First patient enrolled in PRIME Study of AVP-923 in MS central neuropathic pain
Avanir Pharmaceuticals, Inc. AVNR -0.69% today announced the enrollment of the first patient in the PRIME study. The PRIME study is a Phase II clinical trial investigating the use of AVP-923 for the treatment of central neuropathic pain in patients with multiple sclerosis (MS)."With approximately 400,000 people in the U.S. suffering from MS, there is clearly a need for effective and safe therapies to treat symptoms associated with this disease such as central neuropathic pain," said Andrew Goodman, MD, professor of neurology at the University of Rochester.
"Neuropathic pain remains inadequately treated in many people with MS and significantly interferes with daily functioning of those affected."... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1896